Regulatory Perspectives on Long-Term EVAR Outcomes
Representatives from FDA discuss how “long term” is defined, the goals of and insights from recent panel discussions, use of real-world registries to explore long-term durability, how follow-up can be achieved in the face of real-world challenges, and the agency’s call to action for EVAR implanters.
With Ronald Fairman, MD, and Carmen Gacchina Johnson, PhD
